Tamtam Try Tamtam free
Evotec logo

Evotec account plan

Advancing drug discovery collaboratively

At a glance

Evotec is a Hamburg drug discovery, preclinical and biologics manufacturing partner to pharma and biotech, with FY2025 revenue of € 788.4 m.

Evotec SE, headquartered in Hamburg, sells drug discovery, preclinical development and biologics development and manufacturing to pharmaceutical and biotechnology companies, through stand-alone services or collaborative partnerships. In FY2025 it generated revenue of € 788.4 m, adjusted Group EBITDA of € 41.1 m and a net loss of € (103.5) m, with 4,553 employees at 14 sites in eight countries at year-end. US customers accounted for 56% of revenue, Europe 34% and the rest of the world 10%. It served 735 customers in 2025, and its top-10 customers made up 61% of revenue, with Bristol Myers Squibb and Sandoz each above 10%.

Business units

Strategic priorities

Horizon transformation
Announced March 10, 2026, Horizon cuts the footprint from 14 to 10 sites, removes about 800 positions, creates Centers of Excellence and targets about € 75 m run-rate savings by end-2027. By end-September 2026 more than 20% of the savings had been delivered and about 400 positions cut.
Asset-lighter JEB that monetises its technology
JEB is shifting from a capacity-constrained manufacturing model to licensing its technology, including the turnkey J.TRAIN offer launched June 30, 2026. Non-Sandoz, non-DoW JEB revenue grew by more than 60% in 2025 and was guided to grow about 40% in 2026.
2030 mid-range framework
Around 1 billion euros of group revenue by 2030 and an adjusted EBITDA margin of 20% by the end of 2028, above 20% by 2030, with a 40/20/40 mix between the D&PD base business, D&PD strategic partnerships and JEB.
D&PD commercial execution
An upgraded commercial organisation under Chief Commercial Officer Dr Ashiq Khan; D&PD base net sales rose 24% over nine months of 2026, inbound leads by more than 45%, and around 20 strategic partnership opportunities represent approximately 1 billion euro of potential deal value.
Focused science and AI
Science focus narrowed to AI-driven innovation, molecular glue degraders and targeted protein degradation, with an Innovation Board set up in 2025 and Rui Wang appointed EVP, Head of Global In Silico and AI.

Latest results

For the first nine months of 2026, group revenue fell 13.1% to € 465.0 m (9M 2025: € 535.1 m), with D&PD at € 348.2 m (-11.2%) and JEB at € 117.1 m (-18.3%), the latter reflecting the USD 25 m Sandoz licence sale recognised in Q1 2025. Adjusted Group EBITDA was € (44.3) m and the net loss € 195.3 m, after € 91.9 m of Horizon reorganisation costs and a € 42.3 m Hamburg laboratory impairment. Q3 2026 alone showed revenue of 164.9 million euros and adjusted EBITDA of minus 1.6 million euros, bringing the group close to break-even. FY2026 guidance, cut on July 13, was reaffirmed at revenue € 570-610 m and adjusted EBITDA € (70)-(105) m, with both expected toward the upper end. Liquidity stood at € 400.9 m.

Investments and deals

Toulouse J.POD sale to Sandoz
Closed December 5, 2025 for about USD 350 m in cash plus upfront licence fees; Evotec is eligible for more than USD 300 m in further licence and development payments and royalties on up to ten biosimilars.
Third manufacturing train at J.POD Redmond
After Vertex Pharmaceuticals selected JEB for commercial manufacturing of its kidney-disease biologic, a third train will be added at Redmond, the largest single investment of 2027, with a planned temporary manufacturing pause in 2027.
Capex discipline
Capex was cut to € 72.5 m in 2025 (2024: € 117.5 m) and to € (19.2) m in the first nine months of 2026; capex is expected below 10% of revenue in 2026 and beyond.
Equity portfolio exits
Evotec is monetising its venture holdings: the Tubulis stake was sold to Gilead in May 2026 for € 89.3 m net, after the Dark Blue and Carrick Therapeutics sales in 2025; 29 equity engagements remained at end-2025.
Convertible bond to finance Horizon
€ 116.1 m of convertible bonds due 2033 were priced May 21, 2026 to finance Project Horizon.

Challenges and risks

Weak early-stage biotech demand
30-40% of the D&PD customer base faced funding constraints, and D&PD revenue fell on lower sales-to-revenue conversion across all business areas in 2026.
Delayed milestones and partnerships
The July 2026 guidance cut was attributed about 40% to delayed milestones in existing partnerships, about 45% to slower new D&PD strategic partnerships and about 15% to weaker conversion.
Customer concentration
43% of 2025 revenue came from three customers, and partnerships can be terminated or scaled back at short notice.
Underutilisation and high fixed costs
D&PD gross margin fell to 8.8% in 2025 and the group gross margin was 3.6% for 9M 2026 amid continued underutilisation, with a high fixed cost base amplifying revenue shortfalls.
Competition and FX
Competition from cost-conscious CROs in Asia and Eastern Europe and AI-focused biotechs building wet labs; 65% of revenue is in USD.

What leadership says

“Horizon is a defined time-bound realignment with a clear end state. We plan to execute swiftly and only once.”

Christian Wojczewski, Chief Executive Officer · Q4 and Full-Year 2025 Results Call, April 8, 2026

“Importantly, these revenues are delayed, not lost and are expected to be recognized in 2027 rather than 2026.”

Christian Wojczewski, Chief Executive Officer · Analyst call on preliminary H1 2026 results, July 14, 2026

“Horizon is moving from implementation into tangible delivery”

Christian Wojczewski, Chief Executive Officer · Q3 and Nine-Month 2026 Results Call, November 5, 2026

“illustrates the attractiveness of our continuous manufacturing technology and validates JEB as a core pillar of our future growth ambitions”

Christian Wojczewski, Chief Executive Officer · Integrated Annual Report 2025, on the Sandoz agreement

Where a supplier can help

Site consolidation and Centers of Excellence
Horizon closes four sites and consolidates capabilities into Centers of Excellence; suppliers of lab relocation, equipment, facility and transition services can support the move from 14 to 10 sites.
Commercial organisation build-out
The upgraded commercial organisation under a new CCO, with rising inbound leads and around 20 partnership opportunities, creates needs for sales tooling, CRM, pipeline analytics and business development support.
Redmond capacity expansion
The third manufacturing train at J.POD Redmond for Vertex's commercial biologic opens room for bioprocess equipment, single-use consumables, engineering and validation suppliers.
Cost savings programme
The € 75 m run-rate savings target and high fixed cost base favour vendors offering procurement savings, automation of standard offerings and outsourced back-office services.
AI and data generation
The focus on AI-driven innovation and the Molecular Patient Database invites data infrastructure, analytics and in-silico tooling providers that can support the new Global In Silico and AI function.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like Evotec?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about Evotec

What does Evotec do?

Evotec provides drug discovery, preclinical development and biologics development and manufacturing to pharma and biotech companies. It reports two segments: Discovery & Preclinical Development and Just – Evotec Biologics.

What is Evotec's revenue?

FY2025 revenue was € 788.4 m with adjusted Group EBITDA of € 41.1 m. For FY2026 the company guides revenue of € 570-610 m.

How many employees does Evotec have?

Evotec had 4,553 employees at 14 sites in eight countries at end-2025; average headcount for the first nine months of 2026 was 4,379.

What is Evotec's strategy?

The Horizon programme cuts the footprint to 10 sites and targets about € 75 m run-rate savings by end-2027, while JEB moves to an asset-lighter licensing model. The 2030 ambition is around 1 billion euros of revenue.

Who leads Evotec?

Dr Christian Wojczewski is CEO, Claire Hinshelwood CFO, Dr Ingrid Müller COO and Dr Joanna Holbrook CSO from November 1, 2026. Dieter Weinand chairs the Supervisory Board.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)